On Monday, November 27th, the Food and Drug Administration (FDA) released documents relating to the Agency’s assessment of the risk of acquiring variant Creutzfeld-Jakob Disease (vCJD), a human form of mad cow disease, for persons with bleeding disorders who have used US licensed plasma-derived factor VIII products (pdFVIII).
On September 21, 2004, United Kingdom (UK) health authorities informed people with hemophilia and other bleeding disorders that they are considered "at risk" for variant Creutzfeldt-Jakob Disease (vCJD) if they used UK plasma products manufactured between 1980 and 1998. These products were made from plasma collected from donors in the UK who were later identified to have vCJD or possibly from donors who still remain asymptomatic for vCJD.
The National Hemophilia Foundation has been contacted by several hemophilia treatment centers (HTC) regarding a "beige substance" on the tip of butterfly needles distributed by a former Abbott division now an independent company called Hospira.
The National Hemophilia Foundation (NHF) has been notified by ZLB Behring that a single lot of hemophilia clotting factor manufactured in 1996 by its predecessor company, Centeon, has been linked to a French donor who later developed variant Creutzfeldt-Jakob Disease (vCJD).
The Food and Drug Administration has issued a nationwide alert against the use of all lots of preloaded syringes containing either heparin or sodium chloride intravenous catheter flushes manufactured by IV Flush, LLC because new cases of infection associated with use of these possibly contaminated products have been reported.